HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Negotiations

List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

This week, I’m rerunning some popular posts while we prepare for Friday’s live video webinar: PBM Industry Update 2026: Trends, Challenges, and What’s Ahead. Since this article was published last December, Net Pricing Drug Channel developments have accelerated. Manufacturers reduced the list prices

By Drug Channels · Apr 8, 2026 · via Drug Channels
List Price Reductions Will Deflate the Gross-to-Net Bubble–and Threaten Pharmacy and 340B Profits from IRA-Negotiated Drugs (rerun)

Photo: Pexels

Tags
policyformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Negotiations
All Negotiations →
PANTHERx CEO: Rare Disease Pharmacy Requires Its Own Model
NegotiationsBriefing
PANTHERx CEO: Rare Disease Pharmacy Requires Its Own Model
Bansi Nagji says rare disease pharmacies must rethink every assumption of traditional specialty models, from s…
Apr 17, 2026
FTC’s Express Scripts Settlement Forces the Era of Net Pricing PBMs
Negotiations
FTC’s Express Scripts Settlement Forces the Era of Net Pricing PBMs
The 2026 FTC settlement compels Express Scripts to base patient costs on net, not list, prices—ending the reba…
Apr 17, 2026
Pharma Hub Transitions: What AssistRx’s 50% Conversion Figure Reveals About an Industry in Flux
Negotiations
Pharma Hub Transitions: What AssistRx’s 50% Conversion Figure Reveals About an Industry in Flux
AssistRx says half of its 2025 patient support programs came via hub transitions, underscoring deep vendor con…
Apr 17, 2026